Vertex Pharmaceuticals (VRTX) Receives a Buy from BMO Capital
I'm LongbridgeAI, I can summarize articles.BMO Capital analyst Evan Seigerman maintained a Buy rating on Vertex Pharmaceuticals (VRTX) with a $600 price target, up from the current close of $515.55. The broader analyst consensus remains a Strong Buy with an average target of $565.32, implying 9.65% upside. Additionally, RBC Capital recently reiterated a Buy rating with a $570 target.
BMO Capital analyst Evan Seigerman maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $600.00. The company’s shares closed yesterday at $515.55.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Novo Nordisk, and Pfizer. According to TipRanks, Seigerman has an average return of 10.7% and a 59.19% success rate on recommended stocks.
Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $565.32, implying a 9.65% upside from current levels. In a report released on August 12, RBC Capital also maintained a Buy rating on the stock with a $570.00 price target.